A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants (TRILOGY)
Last Updated April 17, 2025
Want to learn how to participate in this trial?
CNTO1959ISD3001
OVERVIEW
-
Sexes Eligible for Study
all -
Age
years -
Phase
phase 33 -
Sites
Sites -
Status
Recruiting
SUMMARY
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).
CONDITIONS
- Crohn's Disease
- Colitis, Ulcerative
- Arthritis, Psoriatic
- Arthritis, Juvenile
ELIGIBILITY
Inclusion Criteria:
* Must have completed the dosing planned in the primary pediatric guselkumab study
* Must have received benefit from continued guselkumab therapy in the opinion of the investigator
* Before enrollment, a participant must be either: (a) Not of childbearing p
DETAILS
LOCATIONS
Country (3) | City or Province (3) | Status |
Spain | Santiago de Compostela Hosp. Clinico Univ. de Santiago |
RECRUITING
|
United States | Salt Lake City University of Utah |
RECRUITING
|
China | Changzhou Changzhou No 2 Peoples Hospital |
RECRUITING
|
42.88052, -8.54569
40.76078, -111.89105
31.77359, 119.95401
Indicates 50+ sites in this region: click to zoom in.
Indicates 10+ sites in this region: click to zoom in.
Indicates < 10 sites in this region: click to zoom in.
Corresponds to individual site.